Xilio Therapeutics
XLOClinical Pipeline
No assets found matching the corporate key (XLO)
Financial Statements & Analysis
Total Gross Revenue
$8.08M $19.07M $43.77M $12.65M
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($15.33M) ($14.32M) ($56.04M) ($19.83M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($7.12M) ($6.67M) ($29.71M) ($6.93M)
Operating Income / (Loss)
($14.37M) ($1.93M) ($41.98M) ($14.11M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
($1.48M) ($14.36M) $6.95M $4.58M
Income Tax Provision / (Benefit)
— — $0.00M —
NET INCOME / (NET LOSS)
($15.84M) ($16.29M) ($35.04M) ($9.53M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$121.6M$103.8M$137.5M$150.3M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$121.6M$103.8M$137.5M$150.3M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$2.2M$2.8M$2.5M$3.9M
Total Current Assets
$123.7M$124.1M$145.0M$154.2M
Property, Plant and Equipment, Net
$4.0M$3.7M$3.9M$3.7M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$133.8M$133.7M$154.7M$163.5M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$4.1M$2.3M$3.2M$1.1M
Accrued Expenses & Clinical Liabilities
$5.6M$9.0M$11.7M$9.0M
Total Current Liabilities
$53.3M$56.4M$56.3M$43.0M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
$28.6M$25.5M$20.6M$16.5M
Other Long-Term Obligations
$44.9M$59.9M$42.5M$31.5M
Total Liabilities Block
$126.7M$141.8M$119.4M$90.9M
Total Stockholders' Equity
$7.1M$-8.1M$35.3M$72.5M
TOTAL LIABILITIES & EQUITY
$133.8M$133.7M$154.7M$163.5M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
2.32x 2.20x 2.58x 3.59x
R&D Expenditure Flow
$23.6M$37.9M$56.0M$19.8M
Net Income / (Loss)
($15.84M) ($16.29M) ($35.04M) ($9.53M)
Depreciation & Amortization
$0.88M $1.22M $1.54M $0.34M
Stock-Based Compensation
$2.89M $4.01M $6.94M $2.21M
Change in Accounts Receivable
— $17.50M $5.00M ($5.00M)
Change in Prepaid Assets / Expenses
($3.08M) ($2.58M) ($3.08M) $1.21M
Change in Payables & Clinical Accruals
$1.52M ($0.28M) $0.15M ($1.68M)
Other Operating Source / (Use) Changes
$28.14M ($6.58M) $19.49M ($9.89M)
Net Cash from Operating Activities
$14.50M ($2.99M) ($4.99M) ($22.34M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
($0.42M) ($0.42M) ($0.52M) ($0.56M)
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
($0.42M) ($0.42M) ($0.52M) ($0.56M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
— — — —
Net Cash from Financing Activities
$52.19M $51.91M $87.78M $35.71M
NET CONSOLIDATED CHANGE IN CASH
$66.27M $48.49M $82.27M $12.81M
Clinical Trials Registry
No active clinical trials detected in data stream.